However, PD‐1 blockade monotherapy did not show OS benefits for SCLC when used as the second‐line or later‐setting therapeutic option, which may be due to insufficient lymphocyte infiltrations in SCLC.26, 27. The gene discussed is PDCD1; the disease is small cell lung carcinoma.